|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 403/12 | |
| A61K 31/4155 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3325468 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16745005.5 |
| Europos patento paraiškos padavimo data | 2016-07-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-05-30 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-11-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/042529 |
| Data | 2016-07-15 |
| (87) | Numeris | WO 2017/015124 |
| Data | 2017-01-26 |
| (30) | Numeris | Data | Šalis |
| 201562196087 P | 2015-07-23 | US | |
| 201562248408 P | 2015-10-30 | US | |
| 201562264059 P | 2015-12-07 | US |
| (72) |
STANCATO, Louis Frank, US
|
| (73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (54) | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS |
| CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS |